CN102349920A - Sulfanilamide medicament composition for wound surface - Google Patents
Sulfanilamide medicament composition for wound surface Download PDFInfo
- Publication number
- CN102349920A CN102349920A CN2011102287229A CN201110228722A CN102349920A CN 102349920 A CN102349920 A CN 102349920A CN 2011102287229 A CN2011102287229 A CN 2011102287229A CN 201110228722 A CN201110228722 A CN 201110228722A CN 102349920 A CN102349920 A CN 102349920A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- sulfadiazine
- calcium
- laurocapram
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC1C=NC([N+]S(*(cc2)ccc2N*)(O)=O)N(C)C1 Chemical compound CC1C=NC([N+]S(*(cc2)ccc2N*)(O)=O)N(C)C1 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a sulfanilamide medicament composition for a wound surface. The medicament composition contains sulfadiazine zinc, sulfadiazine silver and laurocapram, and can further contain preservative and medicinal calcium salt. The medicament composition is prepared into clinically acceptable formulations such as gel, mucilage, film coating agent and the like according to a conventional process by adding medicinal auxiliary materials. The medicament composition has strong antibacterial and bacteriostatic effects, obviously shortens the healing time of the wound surface, has good pain easing effect, is safe, effective and convenient to use; and the composition has stable anti-freezing property.
Description
Technical field
The invention belongs to field of medicinal compositions, particularly a kind of sulfonamides compositions, its preparation method and by its pharmaceutical preparation of processing.
Background technology
Silver sulfadiazine (SD-Ag), English Sulfadiazine Silver by name, chemistry N-2-pyrimidine radicals by name-4-aminobenzenesul fonamide silver salt; Molecular formula is C
10H
9AgN
4O
2S, molecular weight: 357.14, chemical structural formula is following:
Silver sulfadiazine is the crystalline powder of white or off-white color, and chance light or chance heat are perishable, in water, ethanol, chloroform or ether, all do not dissolve.
Silver sulfadiazine has extremely strong inhibitory action to burn dominant bacteria bacillus pyocyaneus etc., and silver salt has astriction, can make that burn wound is dry, incrustation and immediate union.
Zinc sulfadiazine (SD-Zn), English name: Sulfadiazine Zinc, chemistry two (N-2-pyrimidine radicals-4-aminobenzenesul fonamide) zinc salt dihydrates by name.Molecular formula: C
20H
18N
8O
4S
2Zn2H
2O, molecular weight: 599.94, its structural formula is:
Zinc sulfadiazine is the crystalline powder of white or off-white color; Odorless, tasteless; Chance light or chance heat are perishable, in water, ethanol, chloroform or ether, all do not dissolve.
The sulfadiazine of zinc sulfadiazine partly has bacteriostasis property.Zinc in the zinc sulfadiazine also has bacteriostasis owing to can destroy the dna structure of antibacterial.Zinc ion is the indispensable trace element of human body, the function of a lot of enzymes in the wide participation internal metabolism, and human body has 20% zinc to concentrate on skin, and the burn and scald patient is in various degree the zinc deficiency state that is in all.Zinc sulfadiazine can improve local zinc amount when protecting from infection, promote the epithelial tissue growth.Use zinc sulfadiazine can compensate the zinc loss, thereby the enhancing body opposing is infected and the ability of wound healing.Zinc sulfadiazine has control infection and the dual-use function that promotes wound healing.
The external single preparations of ephedrine of silver sulfadiazine (SD-Ag) and zinc sulfadiazine (SD-Zn) is usually used in treating empyrosis wound surface clinically to be infected, and outside the decapacitation control infection, also can impel wound surface drying, incrustation and promote healing.Silver sulfadiazine and zinc sulfadiazine compound preparation be the report of existing clinical practice also.
The silver sulfadiazine of existing report and sulfadiazine Zn composition and compound preparation thereof exist the deficiency of different aspect.One Chinese patent application 01107197.4 (publication number CN1312078A) discloses a kind of manufacturing approach of compound sulfadiazine zinc spreader, and this liniment contains the composition of calcium salt and antiseptic, but antifreeze, stabilizing effect is not ideal enough.One Chinese patent application 02160214.X (publication number CN1513458A) discloses a kind of compound sulfadiazine silver zinc ointment machin its preparation method, but skin irritation is big.In the burn and scald therapeutic process, subinfection again of wound surface bacillus pyocyaneus and healing time are very long to be the emphasis problem of this type of disease, also remains further to be captured.
Summary of the invention
One of the object of the invention provides a kind of new sulfonamides compositions, and said composition can be used for preparation treatment burn and scald and other infective wound surface medicines.
Sulfonamides compositions of the present invention contains zinc sulfadiazine, silver sulfadiazine and laurocapram, and wherein the weight ratio of zinc sulfadiazine, silver sulfadiazine and laurocapram is 50～500: 20～250: 3～6; Preferred weight ratio is 200: 100: 4～5; Most preferably weight ratio is 200: 100: 4.5.
Zinc sulfadiazine in the sulfonamides compositions of the present invention both can be that dihydrate also can be an anhydride.The water white thick liquid of laurocapram, almost odorless is tasteless, and proportion is 0.900-0.926 in the time of 25 ℃; Be nonpolar transdermal enhancer, it can make cutin softening, strengthens permeability, improves part or whole body blood drug level, improves the preparation bioavailability.The transdermal enhancing effect and the working concentration of laurocapram are non-linear relation, and according to the difference of medicine, consumption is during greater than optium concentration, and its transdermal enhancing effect descends on the contrary.Research worker of the present invention is surprised to find; Work as zinc sulfadiazine; The weight ratio of silver sulfadiazine and laurocapram is 50～500: 20～250: 3～6 o'clock; Compositions has well antibacterial; Promote the wound healing effect; Be better than not containing the zinc sulfadiazine of laurocapram; The sulfadiazine silver composition; But when the tall and erect ketone too high levels of Laurel nitrogen; The outer time spent; Then produce certain skin irritation; So zinc sulfadiazine in the present composition; The weight ratio of silver sulfadiazine and laurocapram is 50～500: 20～250: 3～6, and preferred weight ratio is 200: 100: 4～5; Most preferably weight ratio is 200: 100: 4.5.Work as external-used burn and scald treating; Slow metabolism when zinc sulfadiazine contacts with wound fluid with silver sulfadiazine; The part medicine can be gone into blood from local absorption; General absorbtivity is lower than 1/10 of dosage; Sulfadiazine blood drug level Yue Keda 10～20mg/L, when wound surface extensive, when dosage is big; Absorbing increases, and blood drug level can be higher.Sulfonamidemia concentration should not surpass 200 μ g/ml, and as surpassing this concentration, adverse reaction rate increases, and toxicity strengthens, and common untoward reaction comprises anaphylaxiss such as visible local irritation, erythra, dermatitis, drug fever, myalgia, serum sickness like response.Skin irritation during the laurocapram too high levels maybe be through making the generation that obviously raises of sulfonamidemia concentration.
Can also contain medicinal calcium salt and antiseptic in the sulfonamides compositions of the present invention.
Said antiseptic can be one or more the combination in methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, butoben, soluble metyl hydroxybenzoate, ethylparaben sodium, soluble propylhydroxybenzoate, nipabutyl sodium, benzoic acid, sorbic acid, the benzalkonium bromide.The preferred methyl hydroxybenzoate of antiseptic.
Said medicinal calcium salt can be one or more the combination in calcium gluconate, Calcium d-tartrate, calcium citrate, polyenoic acid calcium, calcium lactate, calcium chloride, the calcium hydrogen phosphate.The preferred calcium gluconate of medicinal calcium salt.
Calcium is one of indispensable element of human body, and calcium salt is the maximum a kind of inorganic salt of people's in-vivo content, and 1% calcium great majority are ionic condition and are present in skin, soft tissue, extracellular fluid and the blood.Calcium can be kept the contraction of muscle and the transmission of neural impulse; The ability stimulating platelet impels blood clotting, cell adhesion on the wound; Can also control inflammation with edema, keep acid-base balance, suitable additional calcium also can reduce the low excessively tic that causes of calcium content.And antiseptic has the effect of sterilization and anticorrosion.
When containing medicinal calcium salt and antiseptic, the weight portion of each composition does in the drug regimen of the present invention, zinc sulfadiazine 50～500 weight portions; Silver sulfadiazine 20～250 weight portions; Laurocapram 3～6 weight portions, antiseptic 1～20 weight portion, medicinal calcium salt 1～150 weight portion.
The preferred weight mix proportion scheme one of pharmaceutical composition of the present invention:
Zinc sulfadiazine (dihydrate) 400 weight portions, silver sulfadiazine 220 weight portions, laurocapram 3 weight portions, antiseptic 4 weight portions, medicinal calcium salt 45 weight portions.
The preferred weight mix proportion scheme two of pharmaceutical composition of the present invention:
Zinc sulfadiazine (dihydrate) 40 weight portions, silver sulfadiazine 20 weight portions, laurocapram 6 weight portions, antiseptic 14 weight portions, medicinal calcium salt 130 weight portions.
The preferred weight mix proportion scheme three of pharmaceutical composition of the present invention:
Zinc sulfadiazine (anhydride) 280 weight portions, silver sulfadiazine 130 weight portions, laurocapram 5 weight portions, antiseptic 17 weight portions, medicinal calcium salt 3 weight portions.
The most preferred weight proportion of the present composition is zinc sulfadiazine 200 weight portions, silver sulfadiazine 100 weight portions, laurocapram 4.5 weight portions, calcium gluconate 5 weight portions, methyl hydroxybenzoate 8 weight portions.
Sulfadiazine class pharmaceutical composition of the present invention can be through the preparation of following method, directly or adopt The suitable solvent or medium with each composition of compositions according to its mixed.
The medicine that with pharmaceutical composition of the present invention is wound surface such as raw material for treating burn and scald is through extracorporeal bacteria inhibitor test, freezing-thawing test and clinical efficacy checking; Have the bacillus pyocyaneus bacteriostasis by force, shorten the wound healing natural law, safe and non-stimulating; Need not to change dressings, and the characteristic of analgesia, good effect of freezing protection.Really arrive attenuation synergistic, promoted wound healing, shortened the burn and scald treatment phase, helped analgesic effect in the burn and scald therapeutic process.
Another object of the present invention provides a kind of pharmaceutical preparation by sulfa drugs preparation of compositions of the present invention.Pharmaceutical composition of the present invention; Requirement according to target formulation; Through the conventional pharmaceutic adjuvant of the direct or indirect adding of common process, process clinical acceptable forms, as: gel, mucilage, varnish, liniment, lotion, irrigation, enema, patch, suppository.
The present invention further provides a kind of gel of being processed by sulfonamides compositions of the present invention.The main adjuvant of processing gel can be sodium alginate, methylcellulose, sodium carboxymethyl cellulose, hydroxypropyl emthylcellulose, gelatin, carbomer, chitosan, tragakanta etc.
In the specific embodiment of the present invention; Sulfa drugs composition gels of the present invention agent is by zinc sulfadiazine (anhydride) 200 weight portions; Silver sulfadiazine 100 weight portions; Laurocapram 4.5 weight portions; Buddhist nun's platinum methyl ester 8 weight portions, calcium gluconate 5 weight portions, sodium alginate 480 weight portions; Glycerin 950 weight portions, and distilled water is processed in right amount.Distilled water 7500 weight portions are heated to boiling, under agitation slowly add sodium alginate, on boiling water bath, continue to boil molten; To even pasty state; Under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir, continue to boil and weigh after 10 minutes; Add water and supply 10000 weight portions; Be chilled to room temperature, colloid mill breast mill three times, fill; Packing promptly gets gel.
The specific embodiment
Following experiment and embodiment further specify the present invention, but are not construed as limiting the invention.
Embodiment 1
The preparation of sample 1-6
750g is heated to boiling with distilled water; Under agitation slowly add the 50g sodium alginate; On boiling water bath, continue to boil molten,, under agitation add components such as zinc sulfadiazine, silver sulfadiazine, laurocapram to even pasty state; Stir; Continue to boil after 10 minutes and weigh, add water and supply 1000g, be chilled to room temperature; Colloid mill breast mill three times promptly gets sample.Zinc sulfadiazine in each sample, silver sulfadiazine, laurocapram consumption are following:
Sample 1: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 2g
Sample 2: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 0.45g
Sample 3: zinc sulfadiazine (anhydride) 20g silver sulfadiazine 10g laurocapram 0.2g
Sample 4: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 20g
Sample 5: zinc sulfadiazine (anhydride) 20g silver sulfadiazine 10g laurocapram 5g
Sample 6: zinc sulfadiazine (dihydrate) 20g silver sulfadiazine 10g laurocapram 1g
The local irritation test
Animal: rabbit, big ear white race, body weight 2-2.5kg, male and female are regardless of, and are provided by Third Military Medical University's Experimental Animal Center, totally 14, choose 1.5 * 1.5cm for every
2Not damaged depilation district 4-10 piece is taked the contrast of consubstantiality and allosome.
Dosage: 1.0ml/ piece, 4ml-12ml/ time/day of every animals received amount.Route of administration: local coating, the damage zone skin practice are identical.Administration area: 1.5 * 1.5cm
2/ piece, the 4-12 piece/only.Medicine time of contact: 24 hours.Observation index: observed and recorded 1,24,48,72 hours local responses.Observing time: 24,48,72 hours, totally three times.
Test method:
14 of rabbit slough the hair of abdominal part with the NaS paste, and after 24 hours depilation district on inspection, confirms that skin zero damage can use, with rabbit lie on the back be fixed in operating-table after, choose not damaged depilation skin 4-12 piece, every area 1.5 * 1.5cm
2Take the contrast of consubstantiality and allosome, each is tried membrane 0.1ml be coated in and tried on the skin, gently wiped each away by examination membrane through 24 hours with warm saline, carefully observed and recorded 1,24, local skin reaction in 48,72 hours.According to the criterion of skin irritation intensity, the back dermoreaction is evaluated and is kept the score to film at every turn.
Get the best result of observing dermoreaction for twice, again the best result addition of the erythema of commenting note and edema, obatained score is called " directly stimulating number " and estimates by the skin irritation degree of reagent according to exponential size.All indexes be 0 be divided into non-stimulated; Index≤2 are slight the stimulation, and index stimulated for moderate between 3 one 5 minutes; Index>=5 are serious the stimulation.
To the stimulation of injured skin, with injection needle skin is divided into # shape wound at the position of filming, cause damaged skin.To be coated in the skin part of damage by the examination membrane then, other is with above-mentioned.
Table 1: skin irritation intensity criterion
Table 2: be coated with the film test position and arrange
Above-mentioned the test position alternately applies in the ventrimeson both sides by the examination membrane, does the consubstantiality contrast.
Experimental result table 3: rabbit skin irritant reaction situation
# is an injured skin
Illustrate: (1) every kind supplies the examination film to carry out 10 tuerculodermas 14 rabbit respectively, wherein in the consubstantiality controlled trial of 8 rabbit, has 8, in the allosome control experiment of 5 rabbit, has 2.(2) listed mark shows dermoreaction piece number/experiment skin chunk number in the table.
Visible by table 3; Sample 1, sample 2, sample 3, sample 6; To very big part intact skin and injured skin vacuum response all; Only 1/10 rabbit skin is the minimal irritation reaction, and the sample 4 that laurocapram content is high and the appearance minimal irritation reaction times of sample 5 are obviously more than all the other four samples.
Embodiment 2
Sample 7: take by weighing zinc sulfadiazine (dihydrate) 20g, silver sulfadiazine 10g, laurocapram 0.5g, Buddhist nun's platinum methyl ester 0.95g, calcium gluconate 0.4g, sodium alginate 68g, glycerin 135g, distilled water is an amount of.750g is heated to boiling with distilled water; Under agitation slowly add sodium alginate; On boiling water bath, continue to boil molten,, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine to even pasty state; Stir; Continue to boil after 10 minutes and weigh, add water and supply 1000g, be chilled to room temperature; Colloid mill breast mill three times promptly gets sample.
Sample 8: take by weighing zinc sulfadiazine (dihydrate) 20g, silver sulfadiazine 10g, Buddhist nun's platinum methyl ester 0.95g, calcium gluconate 0.4g, sodium alginate 68g, glycerin 135g, distilled water is an amount of.750g is heated to boiling with distilled water; Under agitation slowly add sodium alginate; On boiling water bath, continue to boil molten,, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine to even pasty state; Stir; Continue to boil after 10 minutes and weigh, add water and supply 1000g, be chilled to room temperature; Colloid mill breast mill three times promptly gets sample.
Freezing-thawing test: sample thief 7,8, sampling detects.Carry out freeze thawing 3 times circulation, each circulation should be under-10～-20 ℃ of conditions 2d, under 37 ℃ of conditions, investigate 2d then, after the test once more sampling detect, contain and measure average value measured three times.
Table 4: freezing-thawing test is measured the result
Per sample 7 with the testing result of sample 8, can know that the preparation that adds laurocapram is more stable aspect outward appearance, pH value, silver sulfadiazine and zinc sulfadiazine content under the identical situation of other prescription compositions.
Embodiment 3
Sample 9: take by weighing zinc sulfadiazine (anhydride) 8000g, silver sulfadiazine 4000g, laurocapram 412g, Buddhist nun's platinum ethyl ester 1732g, polyenoic acid calcium 865g, gelatin 8000g, glycerin 5600g, distilled water is an amount of.An amount of distilled water is heated to boiling; Under agitation slowly add gelatin; On boiling water bath, continue to boil molten,, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine to even pasty state; Stir; Add water and supply weight, stir, be chilled to room temperature; Colloid mill breast mill twice, the final 100000g sample that gets.
Sample 10: take by weighing zinc sulfadiazine (anhydride) 8000g, silver sulfadiazine 4000g, Buddhist nun's platinum ethyl ester 1732g, polyenoic acid calcium 865g, gelatin 8000g, glycerin 5600g, distilled water is an amount of.An amount of distilled water is heated to boiling; Under agitation slowly add gelatin; On boiling water bath, continue to boil molten,, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine to even pasty state; Stir; Add water and supply weight, stir, be chilled to room temperature; Colloid mill breast mill twice, the final 100000g sample that gets.
The clinical efficacy experiment: wound surface is with 0.1% bromo geramine, or after the sterilization of 0.05% hibitane, shallow II degree empyrosis wound surface should be cut its epidermis, and dark II degree burn and scald is thoroughly removed beancurd sheet as far as possible, and III degree empyrosis wound surface does not need special handling.Male patient's 89 examples, female patient 76 examples, the age is more than 15 years old below 60 years old, 26.7 years old mean age.Sample directly evenly is applied in wound surface, easy to use, only need getting final product on the uniform coating on the original medicine layer.
Table 5: clinical experiment is comparison sheet as a result
Per sample 9 with the clinical efficacy result of sample 10 relatively; Sample 9 promptly adds the preparation of laurocapram; Wound healing to ulcer, shallow II degree, dark II degree patient and III degree burn and scald patient has facilitation, has shortened the treatment time limit, has alleviated patient's misery.
Embodiment 4
Sample 11: take by weighing zinc sulfadiazine (dihydrate) 40g, silver sulfadiazine 18g, laurocapram 6g, Buddhist nun's platinum methyl ester sodium 14g, Calcium d-tartrate 26g, soluble starch 68g, glycerin 28g, distilled water is an amount of.700g is heated to boiling with distilled water, under agitation slowly adds soluble starch, on boiling water bath, continue to boil molten, to even pasty state; Under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir, add water to supply 1000g; Be chilled to room temperature, stir, promptly get sample.
Sample 12: take by weighing zinc sulfadiazine (dihydrate) 40g, silver sulfadiazine 18g, Buddhist nun's platinum methyl ester sodium 14g, Calcium d-tartrate 26g, soluble starch 68g, glycerin 28g, distilled water is an amount of.700g is heated to boiling with distilled water, under agitation slowly adds soluble starch, on boiling water bath, continue to boil molten, to even pasty state; Under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir, add water to supply 1000g; Be chilled to room temperature, stir, promptly get sample.
External biocidal property experiment: adopt agar dilution to measure minimal inhibitory concentration (MIC).Select for use bacterial strain and agar culture medium to derive from Nat'l Pharmaceutical & Biological Products Control Institute.
Test method: it is 0.5% concentration that sample 11 and sample 12 are used agar culture medium to be diluted to contain principal agent zinc sulfadiazine and silver sulfadiazine weight summation respectively; Dilute with the multiple proportions method again; Process the series concentration of " culture medium-medicine "; The impouring diameter is in the plate of 9cm then; Each plate 20ml, each drug level prepare three parts of parallel culture medium; Cultivated 24 hours for 37 ℃, the asepsis growth person can inoculate each 5 microlitre of five kinds of bacterium liquid, in the agar surface of same drug level.37 ℃ of constant temperature culture 24 h observation results.Lowest concentration of drug with complete antibacterial growth is the minimal inhibitory concentration (MIC) of this sample, repeated experiments three times, observed result.
Table 6: minimum biocidal property (MIC) testing result
The sample 11 that adds laurocapram has surpassed sample 12 to the fungistatic effect of staphylococcus aureus, bacillus pyocyaneus and Hemolytic streptococcus, but identical with sample 12 for colibacillary minimal inhibitory concentration.
Embodiment 5
Take by weighing zinc sulfadiazine (dihydrate) 20g, silver sulfadiazine 10g, laurocapram 0.5g, Buddhist nun's platinum methyl ester 0.85g, calcium gluconate 0.36g, calcium chloride 52g, water-soluble chitosan 146g, distilled water is an amount of.750g is heated to boiling with distilled water, under agitation slowly adds water-soluble chitosan, on boiling water bath, continues to boil molten; To even pasty state, under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir; Add water and supply 1000g, be chilled to room temperature, twice on colloid mill breast mill; With the cleaning, drying of bolt mould, it is inner that liquid paraffin is done lubricant applying and model, to overflowing die orifice slightly, puts coldly in the medicine impouring bolt mould after will the breast mill, and after treating to solidify fully, part is overflowed in excision, opens model, promptly gets the suppository sample.
Embodiment 6
Take by weighing zinc sulfadiazine (dihydrate) 40g, silver sulfadiazine 18g, laurocapram 5g, Buddhist nun's platinum methyl ester sodium 2g, calcium citrate 26g, povidone iodine 8g, glycerin 16g, distilled water is an amount of.Under agitation, continue to stir, add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir, add water to supply 1000g, stir suitably slowly adding glycerin in the distilled water, microporous filter membrane, the aseptic film of crossing promptly gets the irrigation sample.
Embodiment 7
Zinc sulfadiazine (anhydride) 200g, silver sulfadiazine 100g, laurocapram 4.5g, Buddhist nun's platinum methyl ester 8g, calcium gluconate 5g, sodium alginate 480g, glycerin 950g, and distilled water is an amount of.7500g is heated to boiling with distilled water, under agitation slowly adds sodium alginate, on boiling water bath, continues to boil molten; To even pasty state; Under agitation add all the other components such as zinc sulfadiazine, silver sulfadiazine, stir, continue to boil and weigh after 10 minutes; Add water and supply 10000g; Be chilled to room temperature, colloid mill breast mill three times, fill; Packing makes gel.
Claims (9)
1. a sulfonamides compositions contains zinc sulfadiazine 50～500 weight portions, silver sulfadiazine 20～250 weight portions, laurocapram 3～6 weight portions.
2. sulfonamides compositions according to claim 1, zinc sulfadiazine 200 weight portions wherein, silver sulfadiazine 100 weight portions, laurocapram 5 weight portions.
3. according to the arbitrary described pharmaceutical composition of claim 1-2, wherein also contain medicinal calcium salt of 1～150 weight portion and 1～20 weight portion antiseptic.
4. pharmaceutical composition according to claim 3, wherein said medicinal calcium salt is: the combination of one or more in calcium gluconate, Calcium d-tartrate, calcium citrate, polyenoic acid calcium, calcium lactate, calcium chloride, the calcium hydrogen phosphate; Wherein said antiseptic is: the combination of one or more in methyl hydroxybenzoate, ethyl hydroxybenzoate, propylparaben, butoben, soluble metyl hydroxybenzoate, ethylparaben sodium, soluble propylhydroxybenzoate, nipabutyl sodium, benzoic acid, sorbic acid, the benzalkonium bromide.
5. pharmaceutical composition according to claim 4, wherein said medicinal calcium salt is a calcium gluconate; Wherein said antiseptic is a methyl hydroxybenzoate.
6. pharmaceutical composition according to claim 5, zinc sulfadiazine 200 weight portions wherein, silver sulfadiazine 100 weight portions, laurocapram 5 weight portions, calcium gluconate 5 weight portions, methyl hydroxybenzoate 8 weight portions.
7. the clinical acceptable drug preparation processed of the arbitrary described pharmaceutical composition of claim 1-6 is selected from gel, mucilage, varnish, liniment, lotion, enema, patch, suppository, spray.
8. the arbitrary described pharmaceutical composition of claim 1-6 promotes the application in the wound healing medicine in preparation.
9. sulfa drugs composition gels agent contains zinc sulfadiazine 200 weight portions, silver sulfadiazine 100 weight portions; Laurocapram 4.5 weight portions, Buddhist nun's platinum methyl ester 8 weight portions, calcium gluconate 5 weight portions; Sodium alginate 480 weight portions, glycerin 950 weight portions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102287229A CN102349920B (en) | 2011-08-10 | 2011-08-10 | Sulfanilamide medicament composition for wound surface |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102287229A CN102349920B (en) | 2011-08-10 | 2011-08-10 | Sulfanilamide medicament composition for wound surface |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102349920A true CN102349920A (en) | 2012-02-15 |
| CN102349920B CN102349920B (en) | 2013-11-13 |
Family
ID=45573636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102287229A Active CN102349920B (en) | 2011-08-10 | 2011-08-10 | Sulfanilamide medicament composition for wound surface |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102349920B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832750A (en) * | 2016-03-11 | 2016-08-10 | 张晓燕 | Sulfanilamide composite capsule for treating infectious diseases and preparation method thereof |
| WO2020188305A1 (en) | 2019-03-18 | 2020-09-24 | Patsianidi Helen | Ointment for the treatment of burns |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091345A (en) * | 2010-12-28 | 2011-06-15 | 中国人民解放军军事医学科学院野战输血研究所 | Sodium alga acid composition and application thereof |
-
2011
- 2011-08-10 CN CN2011102287229A patent/CN102349920B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102091345A (en) * | 2010-12-28 | 2011-06-15 | 中国人民解放军军事医学科学院野战输血研究所 | Sodium alga acid composition and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 刘吉祥等: "《常用药物辅料手册》", 30 June 2000 * |
| 曾伟强等: "银锌霜的制备和临床应用", 《齐鲁药事》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832750A (en) * | 2016-03-11 | 2016-08-10 | 张晓燕 | Sulfanilamide composite capsule for treating infectious diseases and preparation method thereof |
| WO2020188305A1 (en) | 2019-03-18 | 2020-09-24 | Patsianidi Helen | Ointment for the treatment of burns |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102349920B (en) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7054212B2 (en) | A novel fast-adhesive thin-film forming composition as an effective wound care procedure | |
| CN102387793B (en) | Antiseptic compositions comprising silver ions and menthol and uses thereof | |
| CN105012993B (en) | A kind of cation Medical Living Creature Gum antiseptic dressing and preparation method thereof | |
| JP2018525348A (en) | Mussel adhesion protein product that suppresses skin inflammation and its application | |
| CN106344956A (en) | Chitosan antibacterial gel with effect of promoting healing and method for preparing chitosan antibacterial gel | |
| EP2739275B1 (en) | Antiseptic composition | |
| EA014391B1 (en) | Pharmaceutical composition for treating burns and a method for the production thereof | |
| KR20150013280A (en) | Use of seaprose to remove bacterial biofilm | |
| CN103083472A (en) | Nano silver anti-inflammatory gel for treating gynecologic inflammation and preparation method thereof | |
| CN108158995A (en) | A kind of gynaecology's anti-bacteria foaming agent containing chitosan and preparation method thereof | |
| CN107961399A (en) | A kind of water-based body lotion containing complex antimicrobials | |
| CN105169455B (en) | A kind of burn and scald external application first aid medical dressing and preparation method thereof | |
| CN104173871B (en) | A kind of Chinese medicine composition for treating vulvitis and its application | |
| CN104257684B (en) | Milk cow nipple medicated bath plastics and preparation method thereof | |
| WO2008104076A1 (en) | Electrocolloidal silver and echinacea root antimicrobial formulation | |
| CN108404111B (en) | A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient | |
| RU2485938C1 (en) | Gel-base for wound healing and cosmetic preparation and method of its obtaining | |
| CN102349920B (en) | Sulfanilamide medicament composition for wound surface | |
| CN110269835A (en) | A kind of antibacterial prosthetic gel of carbomer gynaecology and preparation method thereof | |
| CN102405935B (en) | Protamine compounded preparation, preparation method and application thereof | |
| CN110201218A (en) | Liquid adhesive bandage and preparation method thereof | |
| RU2636530C2 (en) | Pharmaceutical compositions for treatment of wounds and burns | |
| CN102283899A (en) | Traditional Chinese medicine external preparation and application thereof | |
| RU2336877C1 (en) | Local antimicrobial agent | |
| RU2146136C1 (en) | Antiseptic "katapel" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 610101 Beijing Road, Longquanyi economic and Technological Development Zone, Chengdu, Sichuan, 166 Patentee after: CHENGDU NO.1 PHARMACEUTICAL Co.,Ltd. Address before: 610101 Beijing Road, Longquanyi economic and Technological Development Zone, Chengdu, Sichuan, 166 Patentee before: CHENGDU NO 1 PHARMACEUTICAL INST Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180815 Address after: 610000 133, east two ring road, Tianpeng Town, Pengzhou, Chengdu, Sichuan, 133 Patentee after: CHENGDU FIRST PHARMACEUTICAL Co.,Ltd. Address before: 610101 Beijing Road, Longquanyi economic and Technological Development Zone, Chengdu, Sichuan, 166 Patentee before: CHENGDU NO.1 PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |